Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APT™ T3X for COVID-19 Prevention
NCT04716426Completed
- Sponsor
- University of Nove de Julho
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, triple-blind trial in coronavirus disease 2019 (COVID-19) comparing Tetracycline hydrochloride 3% with Placebo (2 arms). Primary endpoint: COVID-19 Contamination Rate at 22 days. Started Jan 2021; status: completed.
02
Drugs
tetracycline
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04716426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04716426.